Health & Wellness Community

The All India Institute of Medical Sciences (AIIMS) has developed a new in-house website called readable.com to help youngsters who have been diagnosed with dyslexia read, write, and learn normally. The child neurology department has established an online portal for children with dyslexia, a neurological condition that impacts learning, including oral and written language and makes it challenging to comprehend or read words and/or numbers. “This website will help them read, write and learn like normal children. It is also going to help parents of dyslexic children. Once the parents get familiarised with the app or website, they can teach their children to overcome difficulties in reading and writing,” said Dr Shefali Gulati, professor, department of child neurology. AIIMS has done a research on 44 children who had undergone functional magnetic resonance imaging (F-MRI) while utilising the app before launching the website. The findings indicated that most of the children learned languages and vocabulary just like other children of their own age. According to Gulati, the app’s eight modules, which are creatively presented and cover various language-learning topics, will enable children use artificial intelligence to read, write, and explain things like other children. The app was developed with assistance from IIT-Delhi. This app was a result of a previous partnership between AIIMS and IIT-Delhi to create programmes focused on innovation and rehabilitation. Despite the fact that there is no cure for dyslexia, early diagnosis and treatment can boost children’s reading and writing skills. Before a child starts school, it can be challenging to identify dyslexia symptoms, but there are several warning signs that may point to the condition. Experts claim that some genes that have an impact on how the brain processes language and reading have been linked to dyslexia. These genes also tend to run in families. While most children can read by kindergarten or first grade, dyslexic children usually struggle to understand the fundamentals of reading by that point. Reading problems from childhood persist into adulthood when dyslexia is left undiagnosed and untreated.

According to official sources, the National Technical Advisory Group on Immunization’s Covid working group has examined the data of Biological E’s Corbevax to allow it as a booster for those aged 18 and over completely vaccinated with Covishield or Covaxin. The NTAGI panel did not yet make a recommendation at their meeting on Wednesday. On June 4, the Drugs Controller General of India (DCGI) approved Corbevax as a precautionary dose for individuals 18 years of age and above. Corbevax, India’s first locally produced RBD protein subunit vaccine, is currently being administered to children between the ages of 12 and 14. According to an official source who spoke to the media agency, “The NTAGI panel reviewed the data of Biological E’s Corbevax as a booster for those aged 18 and above fully vaccinated with either Covishield or Covaxin,” In accordance with a 75-day special drive that started on July 15, everyone aged 18 and over is receiving free precautionary doses of the Covid vaccine at government immunisation centres. As part of the government’s Azadi Ka Amrit Mahotsav to commemorate the 75th anniversary of India’s Independence, the “COVID Vaccination Amrit Mahotsava” programme is being undertaken with the intention of increasing the adoption of Covid precaution dosages. To date, the nation has administered more than 6 crore precautionary doses.

India’s COVID-19 immunisation coverage has surpassed 200.61 crore (92.71 crore second dose and 6.11 crore precaution dosage have been provided so far under National Vaccination Drive). There have been 26,04,797 doses given over the past 24 hours. The COVID-19 vaccine’s initial dosage has been given to more than 3.81 crore adolescents so far. 2,64,58,875 sessions have been used to accomplish this. In the past 24 hours, 18,517 patients have recovered, bringing the total number of recovered patients to 4,31,32,140. India now has a recovery rate of 98.47 percent. In the previous 24 hours, 20,557 new cases were reported. The number of active cases in India is presently 1,45,654. Currently, 0.33 percent of all positive cases in the nation are active cases. In the past 24 hours, 4,98,034 COVID-19 tests have been performed. In total, India has performed about 87.06 billion tests to date. Currently, the country’s weekly positivity rate is 4.64 percent, and its daily positivity rate is 4.13 percent.

According to Prime Minister Narendra Modi, the government’s decision to provide free precaution doses of the Covid-19 vaccine to all adults over the age of 18 will increase immunisation rates in India and lead to a healthier nation. All citizens over the age of 18 will receive free precaution doses of the Covid-19 vaccine as part of the “Azadi Ka Amrit Mahotsav” celebrations beginning on July 15 and lasting for 75 days, according to Union minister Anurag Thakur, who announced the initiative after the Union Cabinet approved it earlier in the day on Wednesday. Modi stated in a tweet, “Vaccination is an effective means to fight COVID-19. Today’s Cabinet decision will further India’s vaccination coverage and create a healthier nation.” According to an official source, less than 1% of the target population of 77.10 crore people between the ages of 18 and 59 have received the precautionary dose so far. On April 10, India started vaccinating all adults over the age of 18 with a precautionary dose of the Covid-19 vaccine.

Moderna Inc. announced on Monday that it was moving forward with two Omicron vaccine candidates for the fall, one of which was created to protect against the BA.1 variant and the other to protect against the BA.4 and BA.5. Updated vaccines are being developed by vaccine producers like Moderna and rival Pfizer Inc. to combat the quickly spreading Omicron subvariants BA.4 and BA.5, which have recently expanded to the United States. Moderna claimed that a variety of market preferences for jabs against the subvariants informed its choice to develop the bivalent vaccines. The older 2020 variant and the more recent Omicron variants of the coronavirus are the two separate coronavirus variants that are targeted by bivalent vaccines. New clinical data for Moderna’s BA.1 variant-targeting mRNA-1273.214 vaccination revealed noticeably greater neutralising antibody responses against the fast-spreading BA.4 and BA.5 compared with the currently permitted booster, the firm says. The second booster candidate being researched by the company, mRNA 1273.222, is based on the BA.4/5 strain and is being created in compliance with current guidance from the U.S. Food and Drug Administration. Although the company’s BA.1 subvariant-targeting booster has improved durability and antibody response, according to Jefferies analyst Michael Yee, the original Omicron variant has already moved in the United States, and the FDA is likely to approve future BA.4/5 boosters. Source: Reuters